The latentiation process in drug design.

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2020-12-10T18:00:02Z
dc.date.accessioned2022-12-19T20:07:27Z
dc.date.available2020-12-10T18:00:02Z
dc.date.available2022-12-19T20:07:27Z
dc.date.created2020-12-10T18:00:02Z
dc.date.issued1999-01-01
dc.identifierQuimica Nova. Sao Paulo: Soc Brasileira Quimica, v. 22, n. 1, p. 75-84, 1999.
dc.identifier0100-4042
dc.identifierhttp://hdl.handle.net/11449/195680
dc.identifierWOS:000078164200013
dc.identifier9734333607975413
dc.identifier0000-0003-4141-0455
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5376318
dc.description.abstractShort review about the main aspects of prodrug design, as its objectives, applicability and importance, showing the new trends in the research for selective latent forms, namely targeted drugs.
dc.languagepor
dc.publisherSoc Brasileira Quimica
dc.relationQuimica Nova
dc.sourceWeb of Science
dc.subjectlatentiation
dc.subjectmolecular modification
dc.subjectprodrug design
dc.subjectdrug design
dc.titleThe latentiation process in drug design.
dc.typeOtros


Este ítem pertenece a la siguiente institución